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Abstract 
The trifunctional antibody (trAb) catumaxomab is characterized by a unique ability to 
bind three different cell types: tumor cells; T-cells; and accessory cells. It binds to epithe-
lial cell adhesion molecule (EpCAM) on tumor cells, the CD3 antigen on T-cells, and to 
type I, IIa, and III Fcγ receptors (FcγRs) on accessory cells (e.g. natural killer cells, den-
dritic  cells,  and  macrophages).  Catumaxomab  exerts  its  anti-tumor  effects  via 
T-cell-mediated lysis, antibody-dependent, cell-mediated cytotoxicity, and phagocytosis 
via  activation  of  FcγR-positive  accessory  cells.  Catumaxomab  represents  a 
self-supporting system, as no additional immune cell activation is required for tumor 
eradication. The efficacy and safety of catumaxomab have been demonstrated in a pivotal 
phase II/III study in malignant ascites (MA) and supporting phase I/II studies. It is ad-
ministered as four intraperitoneal (i.p.) infusions of 10, 20, 50, and 150 µg on days 0, 3, 7, 
and 10, respectively. Catumaxomab was approved for the i.p. treatment of MA in pa-
tients with EpCAM-positive carcinomas where standard therapy is not available or no 
longer feasible in the European Union in April 2009. It is the first trAb and the first drug 
in the world approved specifically for the treatment of MA. Catumaxomab was awarded 
the Galen of Pergamon Prize, which recognizes pharmacological research for developing 
new and innovative drugs and diagnostics, in the specialist care category in 2010. The use 
of catumaxomab in other indications and additional routes of administration are cur-
rently being investigated to further exploit its therapeutic potential in EpCAM-positive 
carcinomas. 
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Introduction 
The  development  of  monoclonal  antibodies 
(mAbs),  which  act  via  antibody-dependent 
cell-mediated  cytotoxicity  (ADCC),  represented  a 
significant  advance  in  cancer  immunotherapy.1 
Bispecific  antibodies  (bsAbs),  which  bind  to  tumor 
cells and T-cells, and act via T-cell-mediated lysis, are 
currently in clinical development.2,3 The trifunctional 
antibody (trAb) catumaxomab (Removab®, Fresenius 
Biotech GmbH, Munich, Germany) is characterized by 
a unique ability to bind three different cell types: tu-
mor  cells,  T-cells,  and  accessory  cells.4-6  It  was  ap-
proved in the European Union (EU) in April 2009 for 
the intraperitoneal (i.p.) treatment of malignant asci-
tes  (MA)  in  patients  with  epithelial  cell  adhesion 
molecule  (EpCAM)-positive  carcinomas  where 
standard therapy is not available or no longer feasible. 
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Catumaxomab is the first trAb and the first drug in 
the world approved specifically for the treatment of 
MA. 
Catumaxomab 
Catumaxomab has two different antigen-binding 
specificities: one for EpCAM on tumor cells and one 
for  the  CD3  antigen  on  T-cells.  In  addition,  ca-
tumaxomab binds, via its intact Fc region, to type I, 
IIa, and III Fcγ receptors (FcγRs) on accessory cells, 
e.g. natural killer (NK) cells, dendritic cells (DCs), and 
macrophages.  Catumaxomab  exerts  its  anti-tumor 
effects via T-cell-mediated lysis,7 ADCC, and phago-
cytosis via activation of FcγR-positive accessory cells 
(Figure 1).5,6 Its anti-tumor activity is assisted by the 
induction of T-cell-secreted cytokines, such as inter-
feron (IFN)-γ and tumor necrosis factor (TNF)-α.8 An 
important aspect of catumaxomab’s mode of action is 
that  no  additional  activation  of  immune  cells  is  re-
quired  for  effective  tumor  eradication,  so  it  is  a 
self-supporting system. 
Malignant Ascites 
MA  is  an  increased  accumulation  of  pro-
tein-containing fluid within the peritoneal cavity that 
is caused by i.p. spread of cancer. It is associated with 
advanced ovarian cancer, gastrointestinal malignan-
cies, and other carcinomas, and leads to abdominal 
pain and swelling, dyspnea, nausea, vomiting, mal-
nutrition, and anorexia.9,10 Patients with MA have a 
poor  quality  of  life,9,11  and  a  poor  prognosis,  with 
median  overall  survival  (OS)  of  approximately  1–6 
months.9,12,13 The causes of MA are independent of the 
origin  of  the  primary  tumor  (Figure  2).14-17  Tu-
mor-secreted factors lead to tumor neovascularization 
and increased capillary permeability, resulting in in-
creased  plasma  inflow  into  the  peritoneal  cavity. 
Tumor cells obstruct lymphatic drainage, leading to 
decreased fluid efflux from the peritoneal cavity. 
Rationale for use of Catumaxomab in the 
Treatment of MA 
Prior to the approval of catumaxomab, no agents 
were specifically approved for the treatment of MA 
and  treatment  options,  such  as  peritoneovenous 
shunts,  paracentesis,  and  diuretics,  are  only  pallia-
tive.11 There was thus a need for an effective treatment 
for MA. The rationale for the use of catumaxomab for 
the i.p. treatment of MA was four-fold: 1) epithelial 
tumors  spreading  into  the  peritoneal  cavity  play  a 
major  role  in  the  development  of  MA;  2)  epithelial 
tumors frequently express EpCAM;18-21 3) in the peri-
toneal cavity, EpCAM is a tumor-specific antigen; and 
4) immune effector cells are present in MA.22,23 Tar-
geting  EpCAM  by  i.p.  administration  of  catumax-
omab leads to a depletion of epithelial tumor cells in 




Figure 1. Catumaxomab mechanism of action. ADCC = antibody-dependent cell-mediated cytotoxicity, CK = cyto-
kine, DC = dendritic cell, EpCAM = epithelial cell adhesion molecule, Fcγ R = Fcγ receptor, GM-CSF = granulo-
cyte–macrophage colony-stimulating factor, IL = interleukin, IFN = interferon, LFA = lymphocyte function-associated 





Figure 2. Pathophysiology of malignant ascites. 
 
Table 1. Clinical development of catumaxomab in malignant ascites. 
Study number  Indication 
(No. of treated patients) 
Phase  Study design  Key results 
STP-REM-0124  Malignant ascites due to 
ovarian cancer (23) 
I/II  Multicenter, multinational, 
open label, uncontrolled, 
sequential dose escalation 
Recommended dose 10, 20, 50, 150 µg 
Efficacy: Reduction of ascites flow; no require-
ment for puncture in 22 patients at study end 
IP-REM-PK-01-EU  Malignant ascites due to 
epithelial cancer (13) 
II  Multicenter, open label, 
pharmacokinetic 
i.p. catumaxomab measurable in plasma 
t1/2: geometric mean ~2 days 
High inter-subject variability 
IP-REM-AC-0125  Malignant ascites due to 
epithelial cancer (157) 
II/III  Multicenter, multinational, 
two arm, randomized, open 
label 
Statistically significant and clinically relevant 
superiority of catumaxomab plus paracentesis 
versus paracentesis alone 
 
 
Clinical Development of Catumaxomab in 
MA 
The  clinical  development  of  catumaxomab  in 
MA  consisted  of  three  key  studies:  an  open-label 
phase  I/II  dose-finding  study  (STP-REM-01);24  a 
pharmacokinetic  study  (IP-REM-PK-01-EU);  and  a 
pivotal phase II/III study (IP-REM-AC-01)25 (Table 1). 
A phase II and two phase I studies in other indications 
(ovarian  cancer  [AGO-OVAR-2.10],26  peritoneal  car-
cinomatosis  [IP-REM-PC-01-DE],27  and  in-
tra-abdominal  epithelial  cancers  [IP-REM-GC-01]),28 
provided supporting efficacy and safety data. In total, 
270 patients received catumaxomab in these studies. 
STP-REM-01 
This study investigated the maximum tolerated 
dose (MTD) of catumaxomab in 23 women with re-
current  ascites  due  to  treatment-refractory  ovarian 
cancer.24 Patients received four or five 6-hour i.p. ca-
tumaxomab infusions of 5–200 μg on days 0, 3, 6, and 
9 for the first four dose groups and a fifth infusion on 
day 13 for the fifth dose group. Catumaxomab pro-
duced a significant and sustained reduction in ascites 
flow rate, and 22 patients did not require paracentesis 
between the last infusion and end of the study (day 
37). EpCAM-positive tumor cells in ascites were re-
duced by up to 5 logs and were eliminated to levels 
below  the  limit  of  detection.  The  MTD  was  deter-
mined to be 10, 20, 50, 200, and 200 μg. 
Most  adverse  events  were  reversible  and  re-
solved  without  sequelae.  Frequent  adverse  events 
were transient fever (83%), nausea (61%), and vomit-
ing (57%), which were mostly grade 1/2. Although 
there  was  no  clear  relationship  between  catumax-




is similar to other cancer immunotherapies,29 a dose 
schedule of 10, 20, 50, and 150 μg that is well below 
the MTD was recommended for further studies. 
IP-REM-PK-01-EU 
This was an open-label, multicenter, pharmaco-
kinetic  study  in  13  patients  who  received  four  i.p. 
catumaxomab infusions of 10, 20, 50, and 150 μg. In 
most  patients,  the  catumaxomab  concentration  in-
creased with the number of infusions and the doses 
applied. The highest concentrations of catumaxomab 
were found in ascitic fluid, the site of intended effi-
cacy. Catumaxomab could be detected in plasma after 
the  third  and  fourth  i.p.  infusions,  demonstrating 
systemic  availability.  Inter-patient  variability  was 
high.  The  geometric  mean  maximum  plasma  drug 
concentration  (Cmax)  was  approximately  0.5  ng/mL 
and  the  mean  terminal  plasma  elimination  half-life 
(t1/2) was approximately 2.5 days.30 
IP-REM-AC-01 
This pivotal phase II/III, multicenter study was a 
two-arm,  randomized  (2:1),  open-label  design  that 
compared  catumaxomab  plus  paracentesis  with  pa-
racentesis alone (control) in 258 patients stratified by 
cancer  type  (ovarian  or  nonovarian;  n=129:  85  ca-
tumaxomab/44  control  in  each  group).25  Catumax-
omab was administered as four 6-hour i.p. infusions 
of 10, 20, 50, and 150 µg on days 0, 3, 7, and 10, re-
spectively. Puncture-free survival, defined as the time 
after day 0 (control group)/1 day after last infusion 
(catumaxomab group) to the first need for therapeutic 
paracentesis or death, whichever occurred first, was 
the primary endpoint. Secondary endpoints included 
time  to  next  therapeutic  paracentesis,  ascites  signs 
and  symptoms,  OS,  and  safety.  The main  inclusion 
criteria  were  resistance  to  chemotherapy  or  chemo-
therapy  no  longer  feasible,  at  least  one  previous 
puncture  within  5  weeks  before  screening,  sympto-
matic ascites with a volume of >1 L, EpCAM-positive 
tumor cells in the ascites, and a Karnofsky Index ≥60. 
Catumaxomab  significantly  prolonged  punc-
ture-free  survival  versus  paracentesis  alone  in  the 
intent-to-treat (ITT) population, in the pooled (Figure 
3),  ovarian,  and  nonovarian  cancer  populations  (all 
p<0.0001).  The  median  difference  was  35  (95%  CI: 
25–45), 41 (95% CI: 32–50), and 23 (95% CI: 8–38) days 
in the pooled, ovarian, and nonovarian cancer popu-
lations,  respectively.  The  hazard  ratio  (HR)  for  the 
pooled population corresponded to a risk reduction of 
75% for  puncture  or  death.  Catumaxomab also sig-
nificantly prolonged the median time to next thera-
peutic  paracentesis  versus  paracentesis  alone:  77 
versus 13, 71 versus 11, and 80 versus 15 days in the 
pooled, ovarian, and nonovarian cancer populations, 
respectively  (all  p<0.0001).  This  corresponds  to  a 
saving  of  about  five  punctures  for  catumaxomab, 
which  is  clinically  relevant  as  there  is  continuous 
protein loss with each puncture that leads to cachexia 
and a potential risk of infection and bowel perfora-
tion. 
Ascites  signs  and  symptoms  were  analyzed  8 
days after the last catumaxomab infusion or after day 
0 in the control group.25 Catumaxomab significantly 
(p<0.05) improved ascites-related symptoms in six of 
10  categories  (abdominal  pain,  nausea,  abdominal 
swelling, dyspnea, anorexia, and early satiety) (Figure 
4) and in all four sign categories (abdominal disten-
sion dull to percussion, shifting dullness, fluid thrill, 
and bulging flanks). There was a trend towards pro-
longed  OS  with  catumaxomab,  although  the  study 
was  not  powered  or  designed  to  detect  statistically 
significant differences in OS. Median OS was 72 ver-
sus 68, 110 versus 81, and 52 versus 49 days in the 
pooled, ovarian, and nonovarian cancer populations, 
respectively. In the subgroup of patients with gastric 
cancer, there was a statistically significant difference 
between  catumaxomab  and  paracentesis  alone  (71 
versus  44  days,  p=0.0313).25  A  long-term  survival 
analysis  showed  that  the  6-  and  12-month  survival 
rates for catumaxomab plus paracentesis versus pa-
racentesis  alone  in  the  ITT  population  were  27.5% 
versus 6.7% and 11.4% versus 3.4%, respectively.31 
Catumaxomab had an acceptable safety profile: 
most adverse events were generally mild to moderate 
and fully reversible. The majority of patients (n=131; 
83%) received all four i.p. infusions. The most com-
mon  drug-related  adverse  events  were  cyto-
kine-release-related symptoms (CRRSs), i.e. pyrexia, 
nausea,  and  vomiting,  and  abdominal  pain.  These 
symptoms are due to catumaxomab’s mechanism of 
action  and  are  well-known  side  effects  of  antibody 
therapy.32,33  Transient  increases  in  liver  parameters 
and white blood cell abnormalities occurred but were 
rarely  considered  to  be  clinically  significant.  There 
was  no  distinctive  pattern  of  adverse  events  corre-
sponding to specific infusions. 
The results of this study demonstrated that ca-
tumaxomab, administered as a sequence of four i.p. 
infusions  of  10,  20,  50,  and  150  μg,  had  a  positive 
risk-benefit profile. Catumaxomab plus paracentesis 
resulted in significant prolongation of puncture-free 
survival and puncture-free time, pronounced reduc-
tion of ascites-related symptoms, and improvement in 
OS. The safety profile of catumaxomab is defined by 
its mechanism of action and the i.p. route of admin-
istration. Adverse events are predictable, limited, re-













Figure 4. Ascites-related symptoms in the pivotal phase II/III study.





Figure 5. Overall survival in HAMA-positive versus HAMA-negative patients* in the pooled population in the pivotal 
phase II/III study.
37 *Assessed 8 days after last catumaxomab infusion. 
 
 
Immunological Response to Catumaxomab 
Although  the  induction  of  human  anti-murine 
antibodies  (human  anti-mouse  antibodies  [HAMAs] 
and human anti-rat antibodies [HARAs]) is an intrin-
sic effect of murine mAbs, the available evidence in-
dicates that they are not associated with any major 
safety  issues.34,35  In  fact,  the  development  of  HA-
MAs/HARAs  can  be  associated  with  beneficial  im-
munity and prolonged survival.34,36 A post-hoc anal-
ysis of the pivotal phase II/III trial demonstrated that 
there was a strong correlation between clinical out-
come and humoral response, as measured by the de-
tection of HAMAs 8 days after the fourth catumax-
omab  infusion.37  HAMA-positive  and 
HAMA-negative  catumaxomab-treated  patients  and 
control patients were analyzed separately for punc-
ture-free survival, time to next puncture, and OS, and 
compared with each other. In the pooled population, 
patients who developed HAMAs after catumaxomab 
treatment  showed  significant  improvement  in  all 
three  clinical  outcome  measures  compared  with 
HAMA-negative patients: median puncture-free sur-
vival  was  64  versus  27  days  (p<0.0001;  HR  0.330), 
median  time  to  next  therapeutic  puncture  was  104 
versus 46 days (p=0.0002; HR 0.307), and median OS 
was 129 versus 64 days (p=0.0003; HR 0.433) (Figure 
5).  Similar  differences  were  seen  in  the  ovarian, 
nonovarian, and gastric cancer populations. The re-
sults  showed  that  HAMA  development  may  be  a 
biomarker  for  catumaxomab  response  and  patients 
who developed HAMAs sooner derived greater ben-
efit from catumaxomab therapy. 
EU Approval Procedure 
Catumaxomab was developed and approved in 
the EU for the treatment of MA within 8 years. The 
dose-finding  study  commenced  in  November  2001, 
the pivotal study started in 2004 and reported in 2007, 
and the pharmacokinetic study plus three supporting 
studies were conducted between 2003 and 2007. The 
Committee for Human Medicinal Products (CHMP) 
provided scientific advice, particularly for the design 
of the pivotal study, including the selection of a suit-
able endpoint for MA, as no standards were available 
at the time of catumaxomab’s clinical development. 
The  most  appropriate  endpoint  to  show  potential 
treatment  benefits,  taking  into  account  the  terminal 
nature of the disease, was identified as puncture-free 
survival, a combined endpoint of time to puncture or 
death, whichever occurs first. 
A  Marketing  Authorization  was  compiled  and 
submitted in December 2007 after successful comple-
tion of the pivotal study. CHMP review, which started 
in January 2008, included an assessment of the clinical 
data by the Scientific Advisory Group on Oncology. 
The  CHMP  reached  a  consensus  decision  that  the 
risk-benefit  profile  of  catumaxomab  is  positive  and 
recommended  authorization  in  February  2009.  The 
European Commission followed the recommendation 
of the CHMP and approved catumaxomab (Remov-




tients  with  EpCAM-positive  carcinomas  where 
standard therapy is not available or no longer feasible. 
The approval of catumaxomab was unique for 
several reasons: it is the first drug approved specifi-
cally for the treatment of MA; to date, it is the only 
approved  EpCAM-targeted  antibody;  it  is  the  only 
approved  agent  based  on  the  target  antigen  that  is 
independent of the primary tumor type; and it is the 
first approved trAb. 
Catumaxomab  was awarded  the  Galen  of  Per-
gamon  Prize,  which  recognizes  pharmacological  re-
search for developing new and innovative drugs and 
diagnostics, in the specialist care category in 2010. The 
prize, which is awarded annually by Springer Medi-
cine to honor excellence in pharmacological research 
in Germany, was founded in France in 1970. 
Further Investigations in Malignant Ascites 
Catumaxomab is being investigated in a number 
of clinical studies. CASIMAS (CAtumaxomab Study 
with  Intraperitoneal  infusion  in  Malignant  AScites 
patients) is a randomized, phase lllb study of a 3-hour 
infusion  of  catumaxomab  with  corticosteroid  pre-
medication  in  an  office-based  setting.  The  study  is 
intended  to  further  optimize  the  administration  of 
catumaxomab by reducing the infusion time from 6 to 
3 hours. Repeated catumaxomab treatment cycles are 
being  investigated  in  the  SECIMAS  (SEcond  Cycle 
catumaxomab  Intraperitoneal  infusion  Malignant 
Ascites Safety) study, a follow-on phase ll study to 
CASIMAS.  Patients  needing  their  first  therapeutic 
puncture after treatment in CASIMAS are eligible for 
enrollment in SECIMAS to receive a second i.p. cycle 
of  catumaxomab  10,  20,  50,  and  150  µg.  A 
non-interventional  study  (CARMA)  is  documenting 
treatment behavior. 
Further Development Strategy for Ca-
tumaxomab 
Intravenous infusion is being investigated as an 
additional route for administration in a phase I study 
that started at the beginning of 2011. Other indications 
under investigation for i.p catumaxomab include, for 
example, peritoneal carcinomatosis in gastric cancer. 
All carcinomas that express EpCAM could be future 
targets for catumaxomab therapy. 
Conclusions 
Catumaxomab’s trifunctional mechanism of ac-
tion utilizes the close proximity and local activation of 
T-cells and accessory cells against tumor cells. Its ef-
ficacy is dependent on the presence of immune effec-
tor cells, which confirms the importance of local im-
munostimulatory  effects  (e.g.  cytokine  release  and 
physiological T-cell activation and proliferation) and 
their contribution to anti-tumor activity. Importantly, 
no additional activation of immune cells is necessary 
for  effective  tumor  eradication  by  catumaxomab, 
which is thus a self-supporting system. The efficacy 
and safety of catumaxomab have been demonstrated 
in a pivotal phase II/III study and supporting phase 
I/II studies. It is administered as four intraperitoneal 
(i.p.) infusions of 10, 20, 50, and 150 µg on days 0, 3, 7, 
and  10,  respectively.  Treatment  with  catumaxomab 
significantly  prolongs  puncture-free  survival,  saves 
approximately  five  therapeutic  punctures,  and  im-
proves  ascites-related  symptoms,  with  a  trend  to-
wards prolonging OS. Catumaxomab, which was ap-
proved in the EU in April 2009, is the first trAb to 
receive regulatory approval and the first drug in the 
world approved specifically for the treatment of MA. 
In 2010, catumaxomab was awarded the Galen von 
Pergamon  Prize,  which  recognizes  pharmacological 
research  for  developing  new  and  innovative  drugs 
and diagnostics, in the specialist care category. Clini-
cal development is ongoing in a number of indications 
including MA and peritoneal carcinomatosis. Shorter 
administration  times,  additional  routes  of  admin-
istration, and multiple dosing are under evaluation to 
fully utilize the therapeutic potential of catumaxomab 
in EpCAM-positive carcinomas. 
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